Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

Depomed Inc (NASDAQ:DEPO)

16.32
Delayed Data
As of 4:00pm ET
 -0.51 / -3.03%
Today’s Change
12.25
Today|||52-Week Range
27.02
-9.43%
Year-to-Date
Argos Plummets 72%, Leads Biotech Movers
Feb 22 / TheStreet.com - Paid Partner Content
3 Companies That Need to Kick Their CEO to the Curb
Feb 19 / MotleyFool.com - Paid Partner Content
Depomed Reports 33% Increase in 2016 Net Product Sales
Feb 21 / TheStreet.com - Paid Partner Content
 

Today’s Trading

Previous close16.83
Today’s open16.63
Day’s range16.18 - 16.73
Volume1,757,595
Average volume (3 months)1,668,961
Market cap$1.0B
Dividend yield--
Data as of 4:00pm ET, 02/24/2017

Growth & Valuation

Earnings growth (last year)-161.46%
Earnings growth (this year)+45.08%
Earnings growth (next 5 years)+16.00%
Revenue growth (last year)-12.20%
P/E ratioNM
Price/Sales3.18
Price/Book3.25

Competitors

 Today’s
change
Today’s
% change
XNCRXencor Inc-0.05-0.22%
IPXLImpax Laboratories I...-0.35-2.43%
LOXOLoxo Oncology Inc-0.21-0.50%
SGYPSynergy Pharmaceutic...+0.01+0.18%
Data as of 4:00pm ET, 02/24/2017

Financials

Last reporting dateFebruary 21, 2017
EPS forecast (this quarter)$0.35
Annual revenue (last year)$342.7M
Annual profit (last year)-$75.7M
Net profit margin-22.10%

Profile

Sector
Health Technology
Industry
Pharmaceuticals: Other
President, Chief Executive Officer &
Director
James A. Schoeneck
Chief Financial Officer &
Senior Vice President
August J. Moretti
Corporate headquarters
Newark, California

Forecasts


Search for Jobs